Endocrine Abstracts

Introduction: Diabetic nephropathy (DN) stands as the predominant cause of chronic kidney disease globally. Although therapies targeting the renin-angiotensin-aldosterone system inhibitors (RAASi) offer partial benefits, additionnal strategies are needed. This study was conducted to evaluate the impact of sodium glucose cotransporter 2 inhibitors (SGLT2i) on renal biological parameters.

Methods: We conducted a prospective, evaluative and comparative study at a single center, involving 115 patients with DN matched according to age, sex and stage of DN: Groupe 1 comprised 54 patients on both SGLT2i and RAASi while groupe 2 included 61 patients on RAASi only. The study spanned three periods: T0 at the treatment onset, T1 and T2 after three and six months.

Results: The mean age was 60.2± 9.2 years. Examining the renal effects of SGLT2i, our results indicated a statistically lower albuminuria difference between the two time points (T1-T0 and T2-T0, respectively) in group 1 compared to group 2(P<10^-3). The albuminuria difference between T1 and T0 was -16 (-116-8) for group 1 and 35 (-3-230) for group 2. After 24 weeks, the albuminuria difference between T2 and T0 was -29 (-180-16.5) for group 1 and 50 (-2-207) for groupe 2. Regarding the evolution of creatinine clearance, a non-significant negative difference was noted in both groups between T1 and T0 (P=0.155) after 12 weeks of treatment. However, after 24 weeks of treatment, group 1 exhibited a positive creatinine clearence difference between T0 and T2 in group 1 (0.58 (-5-3)), contrasting with group 2, which maintained a negative differential in creatinine clearance (-0.6 (-5-1)) (P=0.044).

Conclusion: Our findings underscored the role of SGLT2i in treating DN in conjuction with RAASi and their nephroprotective efficacy.